![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Long-Term Tolerability of Elvitegravir/cobicistat/emtricitabine/tenofovir DF Compared to
Efavirenz/emtricitabine/tenofovir DF or Ritonavir-Boosted Atazanavir Plus Emtricitabine/tenofovir DF in Treatment-Naive HIV-1-Infected Subjects
|
|
|
Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 10-13, 2013Denver, CO, USA
P Shalit1, J Gallant2, A Mills3, G Crofoot4, T Nguyen5, H Liu5, M Rhee5, J Szwarcberg5
1Peter Shalit, MD, Seattle, WA; 2Southwest CARE Center, Santa Fe, New Mexico; 3Anthony Mills, MD, Inc., Los Angeles, CA;
4Gordon Crofoot, MD, Inc., Houston, TX; 5Gilead Sciences, Inc., Foster City, CA
![ICAAC1.gif](../images/091213/091213-2/ICAAC1.gif)
![ICAAC2.gif](../images/091213/091213-2/ICAAC2.gif)
![ICAAC3.gif](../images/091213/091213-2/ICAAC3.gif)
![ICAAC4.gif](../images/091213/091213-2/ICAAC4.gif)
![ICAAC5.gif](../images/091213/091213-2/ICAAC5.gif)
![ICAAC6.gif](../images/091213/091213-2/ICAAC6.gif)
![ICAAC7.gif](../images/091213/091213-2/ICAAC7.gif)
![ICAAC8.gif](../images/091213/091213-2/ICAAC8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|